Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
19. Net Loss per Share
- Net Loss per Share
The calculation of basic and diluted earnings per common share is as follows (in thousands, except share data):
| Year Ended December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Numerator: | |||
| Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders, basic | $(547,029) | $(892,869) | $(2,104,929) |
| Less: change in fair value of contingent consideration common shares liability | — | — | 3,143 |
| Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders, diluted | $(547,029) | $(892,869) | $(2,108,072) |
| Denominator | |||
| Weighted average common shares outstanding, basic | 51,894,639 | 48,610,507 | 41,976,537 |
| Effect of dilutive securities: | |||
| Contingent consideration common shares | — | — | 19,435 |
| Weighted average common shares outstanding, diluted | 51,894,639 | 48,610,507 | 41,995,972 |
| Basic net loss per share | $(10.54) | $(18.37) | $(50.15) |
| Diluted net loss per share | $(10.54) | $(18.37) | $(50.20) |
The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders for the periods presented because including them would have been anti-dilutive:
| As of December 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Warrants to purchase Class A common stock | 1,295,622 | 1,295,622 | 1,295,622 |
| Unvested RSUs | 3,327,398 | 3,804,189 | 3,360,911 |
| Earnout shares (1) | 3,794,243 | 3,803,049 | 3,919,517 |
| Outstanding stock options | 767,520 | 192,208 | 317,768 |
| Escrow shares (2) | 20,332 | — | — |
| 9,205,115 | 9,095,068 | 8,893,818 | |
(1)Represents employee and non-employee earnout shares for which the service-based and/or market-based vesting conditions have not been satisfied.
(2)Represents restricted common stock issued in connection with asset acquisitions, held in escrow for indemnification purposes, and subject to forfeiture.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.